Dr. Rajachandran is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Division of Cardiology/ Dept. of Internal Medicine
Texas Tech University Health Sciences Center, El Paso
El Paso, TX 79905Phone+1 915-215-5205Fax+1 915-215-8640
Summary
- Associate Professor Cardiology/Internal Medicine,
Paul L. Foster School of Medicine,
Texas Tech University Health Sciences Center,
El Paso, TX
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Cardiovascular Disease, 1992 - 1995
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1988 - 1991
The Warren Alpert Medical School of Brown UniversityClass of 1988
Certifications & Licensure
PA State Medical License 2010 - 2026
TX State Medical License 2010 - 2026
VA State Medical License 2020 - 2026
CA State Medical License 1992 - 2025
MD State Medical License 2010 - 2023
NJ State Medical License 1999 - 2011
FL State Medical License 1995 - 2002- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
- National Board of Physicians and Surgeons Interventional Cardiology
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site Start of enrollment: 2011 Apr 01
- Cardiovascular Patient Outcomes and Research Team Primary PCI Registry Start of enrollment: 2006 Apr 01
Publications & Presentations
PubMed
- Low-dose Systemic Tissue-type-plasminogen-activator Compared to Conventional Anti-coagulation for the Treatment of Intermediate-high Risk Pulmonary Embolism.Alan De la Rosa, Adrian Rojas Murguia, Michael J Brockman, Debabrata Mukherjee, Manu Rajachandran
Cardiovascular & Hematological Disorders Drug Targets. 2025-01-29 - Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.Manu Rajachandran, Richard A Lange
Current Cardiology Reports. 2024-07-01 - Letter to the Editor: Reduced-Dose Thrombolysis for Acute Pulmonary Embolism.Adrian Rojas Murguia, Debabrata Mukherjee, Chandra Ojha, Manu Rajachandran, Nils P Nickel
Angiology. 2024-03-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
